On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- LDP Group on Generics Calls for Sustainable Supply Scheme: Proposal
June 3, 2021
- Japan to Establish Ecosystem to Deliver Innovative Drugs: Draft Growth Strategy
June 3, 2021
- Deregulation Panel Prods Govt to Fuel SaMD Development
June 3, 2021
- Govt to Build R&D Data Utilization Platform at AMED
June 3, 2021
- Nonpartisan Lawmakers’ Group Launched for Dementia Measures
June 2, 2021
- Japan Cabinet Hammers Out Strategy to Boost Vaccine Development
June 2, 2021
- Japan to Roll Out COVID-19 Vaccines at Workplaces from June 21
June 2, 2021
- Blue Letter Issued to OA Drug Joyclu after Anaphylaxis Reports
June 2, 2021
- Manufacturing and Use of Cannabis-Derived Drugs Should Be Permitted: MHLW Panel
June 2, 2021
- Eisai’s EZH2 Inhibitor, 3 More New Drugs Clear Key Panel, June OK Likely
May 31, 2021
- Panel OK’s Pfizer Vaccine Use in Age 12-Plus, Longer Refrigerator Storage
May 31, 2021
- Olumiant Added to MHLW’s COVID-19 Guide as Approved Drug
May 28, 2021
- LDP Lawmakers Urge Expanded Fertility Treatment Support via Coverage, Subsidies
May 28, 2021
- Japan Approves Rinvoq for Psoriasis, More Drugs for Label Expansions
May 28, 2021
- MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
- Japan Panel Clears 1st Oral SMA Drug, 2 Migraine Meds, RNAi Therapy and More
May 27, 2021
- Next Drug Distribution Confab Set for July 2 after Bid-Rigging Verdicts
May 27, 2021
- Trintellix Braced for Price Cut as Chuikyo OKs CEA Results, Coralan Intact
May 27, 2021
- Chuikyo to Discuss Evaluation Rule for SaMD toward Next Reimbursement Reform
May 27, 2021
- Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
May 26, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…